arXiv · 2010.10517
Scalable HPC and AI Infrastructure for COVID-19 Therapeutics
Abstract
COVID-19 has claimed more 1 million lives and resulted in over 40 million infections. There is an urgent need to identify drugs that can inhibit SARS-CoV-2. In response, the DOE recently established the Medical Therapeutics project as part of the National Virtual Biotechnology Laboratory, and tasked it with creating the computational infrastructure and methods necessary to advance therapeutics development. We discuss innovations in computational infrastructure and methods that are accelerating and advancing drug design. Specifically, we describe several methods that integrate artificial intelligence and simulation-based approaches, and the design of computational infrastructure to support these methods at scale. We discuss their implementation and characterize their performance, and highlight science advances that these capabilities have enabled.
Explore related subjects
Keep this discovery
Hyungro Lee, Andre Merzky, Li Tan, Mikhail Titov, Matteo Turilli, Dario Alfe, Agastya Bhati, Alex Brace, Austin Clyde, Peter Coveney, Heng Ma, Arvind Ramanathan, Rick Stevens, Anda Trifan, Hubertus Van Dam, Shunzhou Wan, Sean Wilkinson, Shantenu Jha. 2020-10-20. Scalable HPC and AI Infrastructure for COVID-19 Therapeutics. https://arxiv.org/abs/2010.10517
Cite the original work for its findings. Save a collection to share your selection of sources.